SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing a period of heightened volume and volatility as investors react to a significant new partnership with Jazz Pharmaceuticals and look ahead to critical clinical readouts later this year. The stock is currently a major focus of community debate, with bulls highlighting the long-term potential of the company's AI-driven drug discovery platform, while bears remain focused on historical underperformance and the risks inherent in upcoming trial data.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focal point for investors speculating on potential partnerships and the company's role as a unique domestic supplier of electrical steel, which is increasingly vital for power grid infrastructure and data centers. While some community members express frustration over management and volatility, others are actively debating whether current stock levels represent a value opportunity amidst ongoing volatility and market-maker influence.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is facing heightened market scrutiny and volatility as investors weigh the company's stabilizing production and significant aircraft backlog against persistent headline sensitivity and concerns regarding regulatory timelines. The community is actively debating the stock's long-term recovery trajectory versus near-term production hurdles, with many participants expressing frustration over the lack of sustained price momentum despite positive order news and defense contract wins.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors remain divided over the company's valuation, recent stock-based compensation, and the ongoing legal challenge regarding CMS reimbursement policies. While the community actively debates whether the stock is significantly undervalued given Ibsrela's revenue growth or if management's spending is stalling momentum, many investors are focused on upcoming clinical trial data and potential legislative action as key catalysts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is facing significant downward pressure following the release of incomplete May sales data, which has exacerbated investor concerns and fueled speculation regarding competitive threats from AstraZeneca's Ultomiris. Despite the negative price action, the community is actively debating the reliability of these sales metrics and looking toward upcoming regulatory milestones, including EMA developments and the activation of the J-Code, as potential catalysts for a recovery.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as a heavily debated value play, with shareholders balancing frustration over stagnant price action and broadband subscriber losses against optimism regarding the company's strong free cash flow, ongoing share buybacks, and profitable growth potential in its theme parks and media divisions. Investors are closely monitoring the upcoming ex-dividend date while discussing the potential for a rebound driven by a low valuation relative to peers.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is currently being driven by heavy institutional rebalancing and speculative interest as traders attempt to navigate volatility stemming from broader geopolitical tensions between the U.S. and Iran. The community is actively debating the reliability of leveraged ETFs in the current environment while watching key technical support levels for signs of a sustained breakout or correction.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as shareholders debate the company's long-term value against a backdrop of stagnant share price performance, despite significant operational expansion and a recent announcement regarding record-breaking non-coffee beverage sales. Investors are actively discussing the frustration of holding through years of sideways movement, while weighing the potential catalysts of a future relisting and the impact of the ongoing share buyback program.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors aggressively hedge against the Nasdaq's technical overextension, with community discussion polarized between those betting on an impending 'AI bubble' burst and those frustrated by the perceived market manipulation and volatility. The conversation is heavily driven by macroeconomic fears, including rising interest rates and geopolitical instability, leading many traders to shift toward inverse ETFs to capitalize on potential downside momentum.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on its inclusion in the Russell 2000 and the potential for a share price surge driven by passive inflows and high short interest. Community discussion remains heavily polarized between bulls anticipating a strategic buyout based on the AXPAXLI clinical data and bears betting against the company's reliance on a single pivotal trial for regulatory approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Benitec Biopharma (BNTC) Expected to Announce Earnings on Wednesday

Benitec Biopharma (NASDAQ:BNTC) will be releasing its Q3 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold rec...

Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving Average - What's Next?

Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above Fifty Day Moving Average - Time to Sell...

Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial

(RTTNews) - Benitec Biopharma Inc. (BNTC) on Monday, announced encouraging interim results from its Phase 1b/2a clinical study evaluating BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy...

Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Benitec Biopharma in a research report on Monday...

HC Wainwright Issues Optimistic Forecast for BNTC Earnings

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for Benitec Biopharma in a research report issued on...

Analysts Issue Forecasts for BNTC Q1 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Benitec Biopharma in a research report...

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One...

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Benitec Biopharma Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.28	--	--	N/A
Q3 '26	-$0.27	-$0.24	10.56%	BEAT
Q2 '26	-$0.22	-$0.26	-16.42%	MISSED
Q1 '26	-$0.45	-$0.22	51.11%	BEAT
Q4 '25	-$0.31	-$0.39	-25.81%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNTCBenitec Biopharma Inc

Upcoming Earnings: Q4 '26

Historical Earnings

Latest BNTC News